FY24 consensus $2.21. Backs FY24 revenue view $58.5B-$61.5B, consensus $60.02B.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Genmab-Pfizer gain full FDA approval for TIVDAK in Metastatic Cervical Cancer
- Labcorp: FDA approves nAbCyte Anti-AAVRh74var HB-FE Assay
- Options Volatility and Implied Earnings Moves This Week, April 29 – May 02, 2024
- PFE Upcoming Earnings Report: What to Expect?
- Pfizer (NYSE:PFE) Notches Up on New FDA Approval